A Canadian biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction treatments for addiction and mental health is opening its doors in London, UK.
Awakn Life Sciences Corp. (NEO: AWKN, Forum) announced that it had received Care Quality Commission's (CQC) formal approval to begin treatments at its flagship location in the city.
The company’s Chief Executive Officer, Anthony Tennyson commented in
a news release that this represents an exciting moment for both his company and for ketamine-assisted therapy overall as it starts to become a more accessible option for patients.
“Most importantly, it provides an effective treatment option for so many when other current therapies or treatments fall short. The CQC giving us this recognition again signals a positive direction for the UK and Europe toward embracing ketamine-assisted therapy as a mainstream treatment.”
Awakn will receive a schedule 2 license from the Home Office which will allow ketamine to be administered in the London clinic, following on from the CQC approval.
The company recently filed
a patent application for a new chemical series of entactogen-like molecules. Entactogen-like molecules are a class of psychoactive substances that produce distinctive emotional and social effects.
The team believes has great potential to treat both substance and behavioural addictions. The company’s patent application covers the new chemical series, fulfils another significant step forward in the development of next generation entactogens and provides a key milestone in Awakn’s drug discovery program.